Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 3/2022

01-04-2022 | COVID-19 | THE CUTTING EDGE: RESEARCH UPDATE

Antibody therapies for treatment of non-severe COVID-19

Authors: Katie Gourlay, Nicholas Taylor, Eddy Lang

Published in: Internal and Emergency Medicine | Issue 3/2022

Login to get access

Excerpt

As the global COVID-19 pandemic reaches its 2nd year, over 270 million cases and 5.3 million deaths have occurred globally. Nearly, 3000 clinical trials have been approved for therapy evaluation, of which approximately 350 evaluate the efficacy of cellular or monoclonal antibody (mAB)-based therapies. …
Literature
1.
Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, Izcovich A, Mangala S, Ge L, Han MA, Agoritsas T, Arnold D, Ávila C, Chu DK, Couban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochwerg B, Switzer C, Vandvik PO, Vernooij RW, Wang Y, Yao L, Guyatt GH, Brignardello-Petersen R (2021) Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ 23(374):n2231. https://​doi.​org/​10.​1136/​bmj.​n2231 (PMID: 34556486; PMCID: PMC8459162)CrossRef
2.
3.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 21(358):j4008CrossRef
4.
5.
Metadata
Title
Antibody therapies for treatment of non-severe COVID-19
Authors
Katie Gourlay
Nicholas Taylor
Eddy Lang
Publication date
01-04-2022
Publisher
Springer International Publishing
Keyword
COVID-19
Published in
Internal and Emergency Medicine / Issue 3/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-022-02959-1

Other articles of this Issue 3/2022

Internal and Emergency Medicine 3/2022 Go to the issue

CE - LETTER TO THE EDITOR

Communication and relationship at time of COVID-19: a possible heritage

IM - ORIGINAL

All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study

EM - ORIGINAL

Psychiatric patients at the emergency department: factors associated with length of stay and likelihood of hospitalization

IM - ORIGINAL

Low eGFR and albuminuria independently predict all-cause mortality in high-risk subjects undergoing coronary arteriography

IM - ORIGINAL

Poor outcome among patients undergoing myocardial perfusion imaging with intermediate-zone troponin

IM - ORIGINAL

Clinical characteristics and tumor markers in ischemic stroke patients with active cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits